AVP-21D9

Home
Ligands
AVP-21D9

GtoPdb Ligand ID: 13720

Synonyms: Thravixa®

Comment: AVP-21D9 is a fully human IgG1 monoclonal antibody that targets the protective antigen (PA) component of Bacillus anthracis toxin [1-2]. It is being developed as an intravenous treatment for anthrax following exposure to B. anthracis.

References
1. Malkevich NV, Hopkins RJ, Bernton E, Meister GT, Vela EM, Atiee G, Johnson V, Nabors GS, Aimes RT, Ionin B et al.. (2014) Efficacy and safety of AVP-21D9, an anthrax monoclonal antibody, in animal models and humans. Antimicrob Agents Chemother, 58 (7): 3618-25. [PMID:24733473]
2. Peterson JW, Comer JE, Noffsinger DM, Wenglikowski A, Walberg KG, Chatuev BM, Chopra AK, Stanberry LR, Kang AS, Scholz WW et al.. (2006) Human monoclonal anti-protective antigen antibody completely protects rabbits and is synergistic with ciprofloxacin in protecting mice and guinea pigs against inhalation anthrax. Infect Immun, 74 (2): 1016-24. [PMID:16428748]

References

1. Malkevich NV, Hopkins RJ, Bernton E, Meister GT, Vela EM, Atiee G, Johnson V, Nabors GS, Aimes RT, Ionin B et al.. (2014)
Efficacy and safety of AVP-21D9, an anthrax monoclonal antibody, in animal models and humans.
Antimicrob Agents Chemother, 58 (7): 3618-25. [PMID:24733473]

2. Peterson JW, Comer JE, Noffsinger DM, Wenglikowski A, Walberg KG, Chatuev BM, Chopra AK, Stanberry LR, Kang AS, Scholz WW et al.. (2006)
Human monoclonal anti-protective antigen antibody completely protects rabbits and is synergistic with ciprofloxacin in protecting mice and guinea pigs against inhalation anthrax.
Infect Immun, 74 (2): 1016-24. [PMID:16428748]